← Back to Search

Monoclonal Antibodies

Bimekizumab for Hidradenitis Suppurativa (BE HEARD I Trial)

Phase 3
Waitlist Available
Research Sponsored by UCB Biopharma SRL
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (day 1) until safety follow-up (up to week 71)
Awards & highlights

Summary

This trial is testing a medication called bimekizumab to see if it is safe and effective for people with moderate to severe hidradenitis suppurativa. Hidradenitis suppurativa is a painful skin condition that causes lumps under the skin. Bimekizumab works by blocking certain proteins that cause inflammation, helping to reduce pain and swelling.

Eligible Conditions
  • Hidradenitis Suppurativa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (day 1) until safety follow-up (up to week 71)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (day 1) until safety follow-up (up to week 71) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of participants achieving clinical response as measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
Secondary study objectives
Absolute change from Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
Absolute change from Baseline in Skin Pain score at Week 16
Percentage of participants achieving Skin Pain response at Week 16
+4 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Bimekizumab dosing regimen 3Experimental Treatment1 Intervention
Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
Group II: Bimekizumab dosing regimen 2Experimental Treatment1 Intervention
Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
Group III: Bimekizumab dosing regimen 1Experimental Treatment1 Intervention
Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
Group IV: Placebo GroupPlacebo Group2 Interventions
Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bimekizumab
2018
Completed Phase 3
~6510

Find a Location

Who is running the clinical trial?

UCB Biopharma SRLLead Sponsor
110 Previous Clinical Trials
21,550 Total Patients Enrolled
3 Trials studying Hidradenitis Suppurativa
1,257 Patients Enrolled for Hidradenitis Suppurativa
UCB CaresStudy Director001 844 599 2273
212 Previous Clinical Trials
44,892 Total Patients Enrolled
3 Trials studying Hidradenitis Suppurativa
1,257 Patients Enrolled for Hidradenitis Suppurativa
~90 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top